Nightstar Therapeutics reported a net loss of $8.1 million, or $0.29 per share, in the second quarter of 2018, compared to a net loss of $4.2 million, or $0.18 per share, in last year’s second quarter.
General and administrative costs rose in the quarter from $0.7 million in 2017 to $3.3 million in 2018. According to a company press release, the increase is due to a $2 million increase in personnel-related costs and a $0.6 million increase in consulting and professional fees.
Research and development costs increased to $8.1 million (Read more...)
Uncategorized